Madrigal Triggers MACD Death Cross, Bearish Marubozu on 15-Minute Chart.

Based on the 15-minute chart, Madrigal's technical indicators have triggered a "MACD Death Cross" and "Bearish Marubozu" at 13:00 on August 21, 2025. This suggests that the stock price has the potential to continue falling, with sellers dominating the market and bearish momentum likely to persist.

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has received a significant boost with the European Commission's conditional marketing authorization for Rezdiffra (resmetirom) to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis [1]. However, technical indicators on the 15-minute chart have triggered a "MACD Death Cross" and a "Bearish Marubozu" at 13:00 on August 21, 2025, suggesting potential continued decline in the stock price [2].

The EU approval makes Rezdiffra the first and only medication approved for MASH treatment in the European Union. The drug is expected to launch in Germany in the fourth quarter of 2025, with plans to expand to other European markets on a country-by-country basis [1]. This approval follows the drug's success in the U.S., where it received an accelerated approval in March 2024 [1].

Despite the positive regulatory news, Madrigal's stock has faced technical challenges. The "MACD Death Cross" and "Bearish Marubozu" indicate that sellers are dominating the market, and bearish momentum may persist. This signals a potential downward trend in the stock price.

Investors should remain cautious and monitor the company's financial performance and regulatory approvals. Madrigal's stock has shown strong performance over the past year, with a 52% return and trading near its 52-week high of $394 [1]. However, the recent technical indicators suggest a need for vigilance.

Analysts have expressed optimism about Madrigal's future prospects. Goldman Sachs, Piper Sandler, and Jefferies have revised their earnings estimates upward and raised their price targets following the EU approval [1]. These developments highlight ongoing interest and confidence in Madrigal's performance.

Madrigal's stock currently trades with moderate debt levels and maintains a healthy balance sheet, crucial factors for its expansion plans [1]. The company's strong financial position, including a current ratio of 5.11, indicates robust liquidity.

Investors should closely watch Madrigal's stock performance and technical indicators. The company's recent regulatory approvals and strong financial position provide a solid foundation, but the technical challenges should not be overlooked.

References:
[1] https://www.investing.com/news/company-news/madrigals-mash-treatment-rezdiffra-receives-eu-approval-93CH-4200708
[2] https://www.nasdaq.com/articles/madrigal-gets-conditional-nod-mash-drug-rezdiffra-eu